Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Accepted/In Press date: 3 July 2023

Published date: 7 August 2023

Additional Information: Funding Information: The trial is implemented by the University of Oxford Primary Care and Vaccines Collaborative Clinical Trials Unit (PCV-CTU) with further support from the Oxford Respiratory Trials Unit and the Centre for Trials Research, Cardiff University, supported by the National Institute of Health and Care Research Clinical Research Network, the National Institute of Health and Care Research and the Department of Health and Social Care (and equivalents in devolved administrations). Funding Information: The authors would like to especially thank all participants in the study and acknowledge the work and support of all participating general practices, NHS COVID-19 treatment services and other health and social care organisations supporting the trial. We would also like to thank our PPI contributors, the Trial Steering Committee, the Data Monitoring and Safety Committee, primary care and other colleagues in the National Institute of Health and Care Research Clinical Research Network, and the National Institute of Health and Care Research. CCB acknowledges part support as senior investigator of the National Institute of Health and Care Research, the NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative (MIC), and the NIHR Health Protection Research Unit on Health Care Associated Infections and Antimicrobial Resistance. RH acknowledges his part-funding from the NIHR Applied Research Collaboration (ARC OxTV) and the NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative (MIC). GH is funded by and NIHR Advanced Fellowship and by the NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative (MIC). JD is funded by the Wellcome Trust PhD Programme for Primary Care Clinicians (216421/Z/19/Z). SP receives support as an NIHR Senior Investigator (NF-SI-0616-10103) and from the UK NIHR Applied Research Collaboration Oxford and Thames Valley. OvH is supported by an NIHR Development and Skills Enhancement Award. KH receives support as an HCRW Senior Research Leader and the Centre for Trials Research receives infrastructure funding from Health & Care Research Wales and Cancer Research UK. OG is funded by ECRAID-Prime (grant number 101046109). Data Monitoring and Safety Committee Independent members: Professor Deborah Ashby (Chair), Professor Benjamin Fisher, Professor Simon Gates, Professor Gordon Taylor, Professor Martin Underwood. Trial Steering Committee Independent members: Philip Hannaford (Chair), Corina Cheeks, Professor Ranjit Lall, Professor Alastair Hay, Professor William Hollingworth, Professor Matthew Sydes: Independent observer, Professor Mike Moore: Independent observer. Funding Information: This work is supported by the UKRI/NIHR, Grant number NIHR135366. Virology team members are partly supported by an MRC COVID modelling grant, Grant number MR/W015560/1. JD is funded by the Wellcome Trust PhD Programme for Primary Care Clinicians (216421/Z/19/Z). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. NH was funded by the Northern Ireland Clinical Research Network, Public Health Agency. OG is funded by ECRAID-Prime (grant number 101046109). Publisher Copyright: © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Keywords: COVID-19, SARS-CoV-2, aged, antiviral agents, humans, middle Aged, prospective studies, randomized controlled trials as Topic, treatment outcome, therapeutics, virology, primary care, clinical trials

Local EPrints ID: 481215

URI: http://eprints.soton.ac.uk/id/eprint/481215

DOI: doi:10.1136/bmjopen-2022-069176

ISSN: 2044-6055

PURE UUID: 1337e07f-2298-4d7c-9a50-1da6f42ddff3

ORCID for Mark Lown: orcid.org/0000-0001-8309-568X

ORCID for Nick Francis: orcid.org/0000-0001-8939-7312

Date deposited: 18 Aug 2023 16:51

Last modified: 18 Mar 2024 03:54